These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26464458)

  • 1. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.
    Köhler S; Cierpinsky K; Kronenberg G; Adli M
    J Psychopharmacol; 2016 Jan; 30(1):13-22. PubMed ID: 26464458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of monoaminergic targets in the antidepressant- and anxiolytic-like effects of the synthetic alkamide riparin IV: Elucidation of further mechanisms through pharmacological, neurochemistry and computational approaches.
    Sartori DP; Oliveira NF; Valentim JT; Silva DMA; Mallman ASV; Oliveira ICM; Chaves RC; Capibaribe VC; Carvalho AMR; Rebouças MO; Macedo DS; Chaves Filho AJM; Fonteles MMF; Gutierrez SJC; Barbosa-Filho JM; Mottin M; Andrade CH; Sousa FCF
    Behav Brain Res; 2020 Apr; 383():112487. PubMed ID: 31987932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT Receptors and the Development of New Antidepressants.
    Ślifirski G; Król M; Turło J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
    Sanchez C; Asin KE; Artigas F
    Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression and serotonin: a never ending story.
    Marazziti D
    Curr Drug Targets; 2013 May; 14(5):513. PubMed ID: 23547753
    [No Abstract]   [Full Text] [Related]  

  • 6. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors).
    Stahl SM
    CNS Spectr; 2015 Apr; 20(2):93-7. PubMed ID: 25831967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular mechanisms of antidepressant drugs.
    Owens MJ
    Depress Anxiety; 1996-1997; 4(4):153-9. PubMed ID: 9166647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressants and serotonergic neurotransmission: an integrative review.
    Willner P
    Psychopharmacology (Berl); 1985; 85(4):387-404. PubMed ID: 2410942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
    Ressler KJ; Nemeroff CB
    Depress Anxiety; 2000; 12 Suppl 1():2-19. PubMed ID: 11098410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action of antidepressants and therapeutic perspectives].
    Bourin M; David DJ; Jolliet P; Gardier A
    Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of models for spontaneous paroxysmal activity in studies of adaptive changes in serotonin receptors].
    Bobula B; Zahorodna A; Tokarski K; Hess G
    Postepy Hig Med Dosw; 2002; 56(3):377-83. PubMed ID: 12194250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin receptor and reuptake sites: pharmacologic significance.
    Gonzalez-Heydrich J; Peroutka SJ
    J Clin Psychiatry; 1990 Apr; 51 Suppl():5-12; discussion 13. PubMed ID: 2157701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic drugs for depression and beyond.
    Stahl SM; Lee-Zimmerman C; Cartwright S; Morrissette DA
    Curr Drug Targets; 2013 May; 14(5):578-85. PubMed ID: 23531115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical alterations of serotonergic neuronal systems in depression.
    Risch SC; Nemeroff CB
    J Clin Psychiatry; 1992 Oct; 53 Suppl():3-7. PubMed ID: 1331029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressants and brain neurochemistry.
    Richelson E
    Mayo Clin Proc; 1990 Sep; 65(9):1227-36. PubMed ID: 2169557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic properties of serotonergic agents and antidepressant drugs.
    Fuller RW
    J Clin Psychiatry; 1987 Mar; 48 Suppl():5-11. PubMed ID: 3493240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction.
    Pehrson AL; Sanchez C
    CNS Spectr; 2014 Apr; 19(2):121-33. PubMed ID: 23903233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine].
    Le Poul E; Lima L; Laporte AM; Even C; Doucet E; Fattaccini CM; Laaris N; Hamon M; Lanfumey L
    Encephale; 1995; 21(2):123-32. PubMed ID: 7781583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression cloning of a serotonin transporter: a new way to study antidepressant drugs.
    Hoffman BJ
    Pharmacopsychiatry; 1994 Jan; 27(1):16-22. PubMed ID: 8159777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.